Other
Immunochemotherapy
0
Pipeline Programs↗
14
Active Trials↗
1
Companies Involved↗
Immunochemotherapy is an early-stage landscape with 0 programs across 1 company. The most active players are Ascentage Pharma Group Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
22
clinical trials
Recruiting11 · 50%
Unknown status4 · 18%
Not yet recruiting3 · 14%
Completed3 · 14%
Withdrawn1 · 5%
Clinical Trials
Trial Activity
22 trials
Neoadjuvant Immunochemotherapy for LAOSCC
Recruiting·—·Phase 3·NCT06258811·134 enrolled
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05980715·324 enrolled
PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07090707·50 enrolled
Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 1/2·NCT07190027·246 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)